$2.1358
Live
Revenue is down for the last 2 quarters, 87.62M → 33.12M (in $), with an average decrease of 62.2% per quarter
Netprofit is up for the last 2 quarters, -40.58M → -4.00M (in $), with an average increase of 912.5% per quarter
In the last 1 year, LifeMD Inc has experienced a drawdown of -5.2%, however 10x Genomics Inc - Class A resisted the overall trend and outperformed by 5.0%
0.0%
Downside
Day's Volatility :1.38%
Upside
1.38%
46.73%
Downside
52 Weeks Volatility :64.6%
Upside
33.54%
Period | LIFEMD INC | Sector (Consumer Staples) | Index (Russel 2000) |
---|---|---|---|
3 Months | 22.47% | 1.9% | -6.7% |
6 Months | -10.29% | -4.9% | -6.2% |
1 Year | -3.11% | -2.1% | -6.3% |
3 Years | 45.33% | 24.0% | 26.9% |
Market Capitalization | 70.3M |
Book Value | - $0.38 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.28 |
Wall Street Target Price | 5.25 |
Profit Margin | -29.44% |
Operating Margin TTM | -23.91% |
Return On Assets TTM | -43.71% |
Return On Equity TTM | -782.48% |
Revenue TTM | 123.1M |
Revenue Per Share TTM | 3.95 |
Quarterly Revenue Growth YOY | 14.099999999999998% |
Gross Profit TTM | 100.4M |
EBITDA | -28.2M |
Diluted Eps TTM | -1.28 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.35 |
EPS Estimate Next Year | -0.25 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.14 |
What analysts predicted
Upside of 145.81%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 5.1M | ↓ 3.51% |
Net Income | -1.2M | ↑ 8.89% |
Net Profit Margin | -23.86% | ↓ 2.72% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.3M | ↑ 64.68% |
Net Income | -1.2M | ↑ 2.89% |
Net Profit Margin | -14.91% | ↑ 8.95% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 12.5M | ↑ 49.79% |
Net Income | -3.1M | ↑ 152.83% |
Net Profit Margin | -25.16% | ↓ 10.25% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 37.3M | ↑ 199.1% |
Net Income | -58.6M | ↑ 1769.4% |
Net Profit Margin | -157.26% | ↓ 132.1% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 92.9M | ↑ 149.04% |
Net Income | -60.9M | ↑ 3.84% |
Net Profit Margin | -65.57% | ↑ 91.69% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 119.0M | ↑ 28.16% |
Net Income | -48.6M | ↓ 20.13% |
Net Profit Margin | -40.86% | ↑ 24.71% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 27.4M | ↑ 9.9% |
Net Income | -18.1M | ↑ 26.18% |
Net Profit Margin | -66.06% | ↓ 8.52% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 29.0M | ↑ 5.93% |
Net Income | -13.3M | ↓ 26.57% |
Net Profit Margin | -45.79% | ↑ 20.27% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 30.5M | ↑ 4.87% |
Net Income | -13.0M | ↓ 2.11% |
Net Profit Margin | -42.74% | ↑ 3.05% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 31.4M | ↑ 3.13% |
Net Income | -8.1M | ↓ 38.1% |
Net Profit Margin | -25.65% | ↑ 17.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 87.6M | ↑ 178.94% |
Net Income | -40.6M | ↑ 403.63% |
Net Profit Margin | -46.32% | ↓ 20.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.1M | ↓ 62.19% |
Net Income | -4.0M | ↓ 90.12% |
Net Profit Margin | -12.1% | ↑ 34.22% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 1.3M | ↑ 60.01% |
Total Liabilities | 641.0K | ↓ 44.34% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.6M | ↑ 107.0% |
Total Liabilities | 1.8M | ↑ 180.26% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.4M | ↑ 31.73% |
Total Liabilities | 4.6M | ↑ 154.7% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 13.1M | ↑ 278.79% |
Total Liabilities | 13.9M | ↑ 203.26% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 49.9M | ↑ 282.45% |
Total Liabilities | 24.1M | ↑ 73.72% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 25.7M | ↓ 48.59% |
Total Liabilities | 33.0M | ↑ 36.79% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 49.9M | ↑ 205.31% |
Total Liabilities | 24.1M | ↓ 22.28% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 50.3M | ↑ 0.74% |
Total Liabilities | 33.9M | ↑ 40.79% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 38.0M | ↓ 24.5% |
Total Liabilities | 31.2M | ↓ 8.19% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 33.4M | ↓ 12.14% |
Total Liabilities | 30.3M | ↓ 2.81% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 25.7M | ↓ 23.07% |
Total Liabilities | 33.0M | ↑ 8.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 33.9M | ↑ 31.96% |
Total Liabilities | 41.2M | ↑ 25.05% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -817.2K | ↑ 100.34% |
Investing Cash Flow | 141.4K | ↑ 0.0% |
Financing Cash Flow | 776.0K | ↑ 117.08% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -905.5K | ↑ 10.81% |
Investing Cash Flow | 141.4K | ↑ 0.0% |
Financing Cash Flow | 802.8K | ↑ 3.45% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 251.4K | ↓ 127.76% |
Investing Cash Flow | -100.0K | ↓ 170.7% |
Financing Cash Flow | 775.1K | ↓ 3.45% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.1M | ↓ 4925.47% |
Investing Cash Flow | -798.1K | ↑ 698.14% |
Financing Cash Flow | 21.0M | ↑ 2609.53% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.1M | ↑ 172.72% |
Investing Cash Flow | -3.4M | ↑ 326.28% |
Financing Cash Flow | 68.6M | ↑ 226.81% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.8M | ↓ 21.47% |
Investing Cash Flow | -1.6M | ↑ 84.96% |
Financing Cash Flow | 39.3M | ↑ 12769.63% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.1M | ↑ 38.88% |
Investing Cash Flow | -7.4M | ↑ 367.43% |
Financing Cash Flow | -774.1K | ↓ 101.97% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.1M | ↑ 24.82% |
Investing Cash Flow | -2.5M | ↓ 65.91% |
Financing Cash Flow | -753.4K | ↓ 2.67% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.8M | ↓ 72.51% |
Investing Cash Flow | -2.2M | ↓ 10.87% |
Financing Cash Flow | -862.9K | ↑ 14.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.6M | ↓ 87.03% |
Investing Cash Flow | -1.8M | - |
Financing Cash Flow | 12.0M | ↑ 3482.61% |
Sell
Neutral
Buy
LIFEMD INC is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() LIFEMD INC | 38.85% | -10.29% | -3.11% | 45.33% | 83.35% |
![]() R1 RCM Inc | 3.35% | 77.46% | -25.2% | 51.08% | 100.5% |
![]() 10X Genomics Inc | 0.9% | 36.78% | 3.3% | -35.47% | 0.25% |
![]() Veeva Systems Inc. | -8.07% | -13.07% | -2.81% | -24.42% | 115.05% |
![]() GE HEALTHCARE TECHNOLOGIES INC. | -2.91% | 29.66% | 29.66% | 29.66% | 29.66% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() LIFEMD INC | NA | NA | NA | -0.35 | -7.82 | -0.44 | 0.0 | -0.38 |
![]() R1 RCM Inc | 128.18 | NA | 0.77 | 0.04 | -0.06 | 0.04 | 0.0 | 6.5 |
![]() 10X Genomics Inc | NA | NA | NA | -1.42 | -0.22 | -0.11 | 0.0 | 6.91 |
![]() Veeva Systems Inc. | 54.08 | 54.08 | 1.27 | 4.18 | 0.15 | 0.07 | 0.0 | 23.48 |
![]() GE HEALTHCARE TECHNOLOGIES INC. | 21.37 | 21.37 | NA | 3.73 | 0.16 | 0.06 | 0.0 | 14.72 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() LIFEMD INC | Buy | $70.3M | 83.35% | NA | -29.44% |
![]() R1 RCM Inc | Buy | $6.7B | 100.5% | 128.18 | -4.41% |
![]() 10X Genomics Inc | Buy | $6.1B | 0.25% | NA | -32.51% |
![]() Veeva Systems Inc. | Buy | $26.5B | 115.05% | 54.08 | 22.63% |
![]() GE HEALTHCARE TECHNOLOGIES INC. | Buy | $35.7B | 29.66% | 21.37 | 9.17% |
Royce & Associates, LP
B. Riley Financial Inc
Vanguard Group Inc
Shah Capital Management
BlackRock Inc
American Financial Group Inc
LIFEMD INC’s price-to-earnings ratio stands at None
Read MoreLifeMD, Inc. (formerly Conversion Labs) is a leading telehealth company that is transforming the healthcare landscape with direct-to-patient product and service offerings. LifeMD's telemedicine platform enables virtual access to affordable and convenient medical treatment from licensed providers and, when appropriate, prescription medications and over-the-counter products delivered directly to the patient's home.
Organization | LIFEMD INC |
Employees | 199 |
CEO | Mr. Justin Schreiber |
Industry | Healthcare |
First Majestic Silver Corp
$5.73
-0.35%
ONYX ACQUISITION CO. I
$10.49
-4.64%
Diversified Healthcare Trust
$1.18
+3.51%
ALTC ACQUISITION CORP-CL A
$10.70
+0.47%
iShares Morningstar Value ETF
$63.28
-0.21%
Nationwide Nasdaq-100 Risk-Managed Income ETF
$20.52
+0.2%
ENFUSION INC
$7.73
-1.9%
WisdomTree Trust - WisdomTree International Quality Dividend Growth Fund
$33.66
-0.59%
GIGACLOUD TECHNOLOGY INC
$6.58
+2.02%